CASI Pharmaceuticals - Evomela launch underway
CASI has announced that it launched Evomela China, making it officially a commercial stage company. The product for multiple myeloma was approved in China under priority review and will be the first formulation of melphalan available. Additionally, the company continues to expand its R&D operation with the licensing of the worldwide rights to a CD19 CAR-T (CNCT19) from the Chinese cell therapy developer Juventas. The company acquired the rights to the pre-Phase I asset for an ¥80m (US$11.6m) investment in Juventas and it owes undisclosed milestones and royalties.CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. The company's primary product and candidates in hematology/oncology include: EVOMELA (Melphalan for Injection), an intravenous formulation of melphalan commercialized in the multiple myeloma treatment setting in the United States; CNCT19, which targets CD19, a B-cell surface protein expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies; CID-103, an investigational anti-CD38 monoclonal antibody being developed for the treatment of patients with multiple myeloma.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.